Pneumococcal Vaccines Market (Product Type - Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine; Distribution Channel - Clinics, Hospitals, Non-governmental Organizations, and Government Authorities): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Pneumococcal Vaccines Market (Product Type - Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine; Distribution Channel - Clinics, Hospitals, Non-governmental Organizations, and Government Authorities): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Report Code: IGR01354 Category: Healthcare & Medical Devices Published: November, 2023

A recent report published by Infinium Global Research on pneumococcal vaccines market provides in-depth analysis of segments and sub-segments in the global as well as regional pneumococcal vaccines market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional pneumococcal vaccines market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global pneumococcal vaccines market.

Market Insight:

The global pneumococcal vaccines market was valued at USD 7.82 billion in 2022 and is expected to reach USD 11.51 billion in 2030, with a CAGR of 4.20% during the forecast period 2023-2030.

Pneumococcal vaccines are immunizations designed to protect against infections caused by Streptococcus pneumoniae bacteria. These vaccines work by stimulating the immune system to produce antibodies that can combat the bacteria, thereby reducing the risk of pneumococcal diseases such as pneumonia, meningitis, and sepsis. There are two main types of pneumococcal vaccines in use such as the Pneumococcal Conjugate Vaccines (PCV 10/PCV13) and the Pneumococcal Polysaccharide Vaccine (PPSV23). PCV13 is recommended for children aged 6 to 18 and adults with underlying health conditions, while PPSV23 is typically administered to individuals over 65 and, in specific instances, to infants aged over two. The World Health Organization (WHO) advocates the inclusion of pneumococcal conjugate vaccines in routine immunization schedules for children. By immunizing infants and young children, these vaccines help reduce morbidity and mortality rates associated with severe pneumococcal infections. This not only safeguards the health and well-being of the youngest population but also lessens the burden on healthcare systems by diminishing hospitalizations and treatment costs, ultimately contributing to improved public health outcomes.

The increasing incidence of pneumococcal diseases, including pneumonia, sepsis, and meningitis, is a significant catalyst for the expansion of the pneumococcal vaccines market. These vaccines play a crucial role in preventing and reducing the burden of these life-threatening infections, driving their demand and market growth. Additionally, government and private sector initiatives aimed at broadening vaccination programs and extending coverage to previously underserved populations are fueling the growth of the pneumococcal vaccines market. These concerted efforts are increasing accessibility and raising awareness, ultimately leading to a larger market and greater immunization rates against pneumococcal diseases. However, the pneumococcal vaccines market faces hindrances due to the substantial manufacturing expenses involved. The high costs incurred in research, development, and production limit affordability and accessibility, impeding the market's growth and hampering efforts to combat pneumococcal diseases on a broader scale. Although, the pneumococcal vaccines market is witnessing growth opportunities due to innovative vaccine research techniques and rising demand in developing regions. These advancements enhance vaccine efficacy and safety, while the increasing demand in less-developed areas opens new markets, addressing unmet healthcare needs and driving market expansion.

Global pneumococcal vaccines market Size, Share, Trends, Ind | IGR

North America holds the maximum market share in the pneumococcal vaccines market. Increased investment in the R&D sector and favorable government initiatives are the major factors responsible for the growth of the market in the North America region. Pharmaceutical companies in North America actively develop and distribute pneumococcal vaccines. Additionally, stringent regulatory guidelines contribute to the region's leading market share, with established players such as Pfizer and Merck maintaining a strong presence. Moreover, the fastest-growing region for pneumococcal vaccines is Asia-Pacific. This growth is driven by several factors, including increasing awareness of vaccine-preventable diseases, a growing population, and expanding healthcare access in emerging economies. Furthermore, the rising middle class and greater healthcare expenditure contribute to the growing demand for pneumococcal vaccines in this region. As a result, Asia-Pacific is witnessing a rapid increase in market share, with several vaccine manufacturers investing in the region to tap into this significant growth potential.

Report Scope of the Pneumococcal Vaccines Market:

Report Coverage Details
Market Size in 2022 USD 7.82 Billion
Market Size by 2030 USD 11.51 Billion
Growth Rate from 2023 to 2030 CAGR of 4.20%
Largest Market North America
No. of Pages 180
Market Drivers
  • Rising prevalence of pneumococcal diseases such as pneumonia, sepsis, and meningitis is a major driving factor for the growth of pneumococcal vaccines market.

  • Government and private sector efforts to expand vaccination initiatives and reach new target demographics are driving growth in the pneumococcal vaccines market.

Market Segmentation By Product Type, and By Distribution Channel
Regional Scope North America, Europe, Asia Pacific, and RoW

Segment Covered

The report on global pneumococcal vaccines market covers segments such as product type, and distribution channel. On the basis of product type, the sub-markets include pneumococcal conjugate vaccine, and pneumococcal polysaccharide vaccine. On the basis of distribution channel, the sub-markets include clinics, hospitals, non-governmental organizations, and government authorities.

Companies Profiled:

The report provides profiles of the companies in the market such as GSK plc, Pfizer Inc., Cochin Shipyard Limited, Serum Institute of India Pvt. Ltd., Merck & Co., Inc., Beijing Minhai Biotechnology Co., Ltd., Astellas Pharma Inc., Walvax Biotechnology Co, Panacea Biotec, and SK bioscience.

Report Highlights:

The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the pneumococcal vaccines market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Frequently Asked Questions (FAQ's)

The global pneumococcal vaccines market was valued at USD 7.82 Billion in 2022.
It is likely to grow at a CAGR of 4.20% during the forecast period 2023-2030.
The global pneumococcal vaccines market is estimated to reach USD 11.51 Billion by the end of 2030.
North America is anticipated to exhibit high demand for pneumococcal vaccines market during the forecast period.
GSK plc, Pfizer Inc., Cochin Shipyard Limited, Serum Institute of India Pvt. Ltd., Merck & Co., Inc., Beijing Minhai Biotechnology Co., Ltd., Astellas Pharma Inc., Walvax Biotechnology Co, Panacea Biotec, and SK bioscience.
CHOOSE LICENCE TYPE

Please Choose One of them.

Google translate
© 2024. Infinium Global Research LLP. All Rights Reserved.